Joel Neal, MD, PhD

Joel Neal, MD, PhD, is a professor of medicine in the Division of Oncology at the Stanford Cancer Institute at Stanford University

Articles

FDA Approval Insights: Taletrectinib in ROS1+ Advanced/Metastatic NSCLC: With Joel Neal, MD, PhD; and Christian Rolfo, MD, PhD

August 28th 2025

Drs Neal and Rolfo discuss the significance of the FDA approval of taletrectinib for the treatment of locally advanced or metastatic, ROS1-positive NSCLC.

Looking Ahead: Future Perspectives and Advancements in EGFRm NSCLC

July 16th 2025

Panelists discuss how future developments in EGFR-mutated non–small cell lung cancer (NSCLC) will focus on biomarker-driven patient selection, rational sequencing strategies, and emerging therapies including cellular therapy and treatments for atypical EGFR mutations.

Balancing Safety and Efficacy With ADC-Based Therapies in Advanced EGFRm Non–Small Cell Lung Cancer

July 16th 2025

Panelists discuss how ADC-based therapies like dato-DXd offer superior efficacy compared with traditional chemotherapy options like docetaxel, while requiring careful monitoring for unique toxicities including ILD, stomatitis, and ocular effects.

TROP2 and Dato-DXd in EGFRm Non–Small Cell Lung Cancer: Evolving Biomarkers and Treatment Strategies

July 9th 2025

Panelists discuss how TROP2-targeted ADC dato-DXd represents another promising option with evolving digital pathology biomarker approaches, though practical implementation and patient selection strategies remain challenging.

Exploring the Potential Role of HER3-DXd in Advanced EGFRm Non–Small Cell Lung Cancer

July 9th 2025

Panelists discuss how HER3-directed ADC patritumab deruxtecan shows promise as a later-line therapy with approximately 30% response rates and intracranial activity, though biomarker selection remains elusive and mechanism of CNS penetration unclear.

Treatment Selection and Sequencing Strategies for Advanced EGFRm NSCLC in the Second-Line Setting

July 2nd 2025

Panelists discuss how second-line treatment selection depends heavily on frontline therapy choice, emphasizing the importance of repeat biopsies to identify resistance mechanisms and considering continuation of TKI with added chemotherapy for patients with controlled CNS disease.

Balancing Safety and Efficacy in the Frontline Management of Advanced EGFRm NSCLC

July 2nd 2025

Panelists discuss how balancing safety and efficacy in frontline regimens involves managing distinct toxicity profiles, with FLAURA2 requiring standard chemotherapy monitoring vs MARIPOSA necessitating complex supportive care for EGFR-related skin toxicity and venous thromboembolism prophylaxis.

Treatment Strategies for EGFRm Non–Small Cell Lung Cancer With Visceral or Oligometastatic Disease

June 25th 2025

Panelists discuss how oligometastatic disease treatment requires careful definition of metastatic burden, with liver metastases potentially indicating more aggressive biology and warranting consideration of intensified frontline therapy.

Optimizing Treatment in EGFRm NSCLC With CNS Metastases: Multidisciplinary Management and Monitoring Strategies

June 25th 2025

Panelists discuss how CNS metastases in EGFR-mutated NSCLC require multidisciplinary management with close radiation oncology collaboration, frequent monitoring, and preference for FLAURA2 regimen due to superior intracranial efficacy data.

MARIPOSA in First-Line EGFRm Non–Small Cell Lung Cancer: Patient Selection and Emerging Survival Data

June 18th 2025

Panelists discuss how the MARIPOSA regimen (amivantamab plus lazertinib) shows promising overall survival benefits in first-line treatment, though with increased toxicity concerns including rash, edema, and VTE risk requiring careful patient selection.

FLAURA2 in the Frontline Management of EGFRm NSCLC: Key Considerations for Patient Selection

June 18th 2025

Panelists discuss how FLAURA2 regimen (osimertinib plus chemotherapy) is being incorporated into frontline EGFR-mutated NSCLC treatment, with considerations for escalating to combination therapy based on disease burden, CNS metastases, and patient tolerance factors.

Dr. Neal on the FDA Approval of Mobocertinib in EGFR Exon 20 Insertion+ NSCLC

September 27th 2021

Joel Neal, MD, PhD, discusses the FDA accelerated approval of mobocertinib in EGFR exon 20 insertion–positive non–small cell lung cancer.

Dr. Neal on Ongoing Trials of Immunotherapy for Lung Cancer

February 11th 2017

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses ongoing trials in immunotherapy for patients with lung cancer.

Dr. Neal on Immunotherapy Combinations in Lung Cancer

October 27th 2016

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses what immunotherapy combinations oncologists are currently using in the treatment of patients with lung cancer.

Dr. Joel Neal on Impact of PD-L1 Tests on Pembrolizumab, Nivolumab Efficacy in Frontline NSCLC

October 12th 2016

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses how PD-L1 testing may have played a role in the survival differences between frontline pembrolizumab and nivolumab in non–small-cell lung cancer (NSCLC).

Dr. Neal on Exciting Advancements in the Field of Lung Cancer

September 28th 2016

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses exciting advancements in the field of lung cancer over the past few years.